Enhancing Early Detection: Innovation, Adherence Challenges, and the Evolving Guidelines in the Global Colorectal Cancer Screening Market
The colorectal cancer (CRC) screening market is undergoing a significant transformation, driven by evolving clinical guidelines and the strategic shift toward greater accessibility and patient adherence, making this a vital public health topic for group discussion. CRC is one of the most preventable, yet third most common, cancers globally, primarily because timely screening allows for the removal of pre-cancerous polyps. The current market is bifurcated between invasive structural tests, such as colonoscopy (the gold standard), and non-invasive stool-based tests, including the Fecal Immunochemical Test (FIT) and multi-target stool DNA tests. The discussion must address the recent downward revision of the recommended starting age for screening, now often 45 instead of 50, in countries like the U.S., which dramatically expands the addressable market and requires a strategic plan for increased resource allocation to handle…